Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00796770 · ClinicalTrials.gov registry record · Phase 1
Vaccination of HIV-1 Infected Patients With Dendritic Cells in Addition to Antiretroviral Treatment - (DALIA Trial)
A Phase 1 study, sponsored by Baylor Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00796770 is a Phase 1 study that has completed, run by Baylor Research Institute. The registered enrollment target is 19 participants.
The verdict
NCT00796770, a Phase 1 study, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the administration of a dendritic cell vaccine is a safe and effective treatment for HIV-1 patients.
Interventions
- BIOLOGICAL Dendritic Cell Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00796770
The ClinicalTrials.gov registry entry for NCT00796770 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dendritic Cell Vaccine is the first listed.
NCT00796770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00796770 about?
NCT00796770 is a clinical study titled "Vaccination of HIV-1 Infected Patients With Dendritic Cells in Addition to Antiretroviral Treatment - (DALIA Trial)". The purpose of this study is to determine whether the administration of a dendritic cell vaccine is a safe and effective treatment for HIV-1 patients.
What is the current status of trial NCT00796770?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2008-11. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00796770?
The interventions under investigation include: Dendritic Cell Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00796770?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.